Infermedica raises $10.2 million
Polish healthtech startup Infermedica has raised $10.25 million in Series A funding. The round was led by the European Bank for Reconstruction and Development (EBRD) and digital health fund Heal Capital, with participation from existing investors Karma Ventures, Inovo Venture Partners, and Dreamit Ventures.
Founded in 2012 in Wrocław, Poland, by Piotr Orzechowski (CEO), Infermedica is an AI-driven platform that delivers symptom triage and instructions so patients can receive the required care. The company operates via a B2B model (counting 60+ clients) and helps insurance, telemedicine companies, and health systems increase efficiency through fast, digital symptom-checks. Clients include Microsoft, Allianz, Global Excel, Sana Kliniken, and Médis.
Infermedica currently employs more than 100 specialists – including doctors, data scientists, and engineers, and doubled their team size in the last year. The platform’s available interfaces include:
- Symptom Checker – a white-label app that provides digital symptom checking and analysis, suggesting a list of the most likely conditions. Symptom Checker is available as a chatbot and voice assistant.
- Call Center Triage – a solution that aids telemedicine personnel to pre-diagnose patients and understand condition severity so they can provide relevant healthcare instructions. Call Center Triage prevents unnecessary urgent care visits, and detects urgent cases quickly.
- Infermedica API – direct access to the engine through a fully-customizable API that can be integrated directly onto clients’ websites, apps or telehealth systems.
“We’re thrilled to welcome EBRD and Heal Capital as new investors on board of our venture. Our mission is to improve quality and access to primary care with the use of AI-powered, constantly improving technology. As we all know, the COVID-19 pandemic has placed great pressure on health systems globally and it’s our obligation to help healthcare providers deliver safe and timely care. This additional funding will enable us to continue developing cutting-edge AI-triage technology and expand our commercial operations in the US and Germany.” – Piotr Orzechowski.